Phase 3 Colorectal Cancer Trial, Recruiting NCT06783491 Sponsor: Maimónides Biomedical Research Institute of Córdoba Condition: Colorectal Cancer
Back to Colorectal Cancer

Phase 3 Colorectal Cancer Trial, Recruiting

NCT06783491
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 to 75 years (people aged 70–75 will be reviewed by a medical committee before being accepted)
  • People diagnosed with a specific type of bowel cancer (adenocarcinoma) located in the colon, sigmoid colon, or the junction between the rectum and sigmoid colon, that has grown into or through the outer lining of the bowel wall, as confirmed by a CT scan or MRI
  • People with a form of this cancer that has grown significantly into the surrounding fat tissue may also be considered (confirm with trial site)
  • People whose cancer has either not spread to nearby lymph nodes, or has spread only to lymph nodes that can be surgically removed, as confirmed by CT scan or MRI
  • People whose cancer has not spread to other parts of the body (no distant metastases)
  • People who are fully active or have only minor restrictions on physical activity (as assessed by a standard medical scale)
  • People whose cancer has a specific genetic profile known as microsatellite stable (pMMR) — this is determined by laboratory testing
  • People who have given their written informed consent to take part

Who may not be able to join:

  • People whose cancer has spread to distant parts of the body, such as the liver or the lining of the abdomen (metastases)
  • People whose cancer is considered unable to be fully removed by surgery, as determined by a specialist medical team
  • People whose cancer has a different genetic profile known as microsatellite unstable (dMMR)
  • People with a deficiency of an enzyme called DPD, which affects how certain chemotherapy medicines are broken down in the body
  • People who have needed emergency surgery to remove the tumour due to a blockage or perforation of the bowel (certain temporary procedures that do not remove the tumour may still be acceptable — confirm with trial site)
  • People with rectal cancer located in the lower or middle part of the rectum (outside the abdominal cavity)
  • People who have another serious cancer at the same time, with some exceptions for certain bowel tumours that may be discussed by the medical committee
  • People with severely reduced liver, kidney, or heart function
  • People who are unable to tolerate the study treatment
  • People who are pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 6 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Alvaro Arjona Sánchez, MD., Ph.D., MAIMONIDES BIOMEDICAL RESEARCH INSTITUTE

Phone: +34957213831

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Maimónides Biomedical Research Institute of Córdoba
Registry
ClinicalTrials.gov
Start date
26 May 2026
Est. completion
1 June 2030

Where this trial is recruiting

🇪🇸 Spain

Primary endpoints

Disease-free survival absolute; Disease-free survival probability

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov